zbMATH — the first resource for mathematics

Examples
Geometry Search for the term Geometry in any field. Queries are case-independent.
Funct* Wildcard queries are specified by * (e.g. functions, functorial, etc.). Otherwise the search is exact.
"Topological group" Phrases (multi-words) should be set in "straight quotation marks".
au: Bourbaki & ti: Algebra Search for author and title. The and-operator & is default and can be omitted.
Chebyshev | Tschebyscheff The or-operator | allows to search for Chebyshev or Tschebyscheff.
"Quasi* map*" py: 1989 The resulting documents have publication year 1989.
so: Eur* J* Mat* Soc* cc: 14 Search for publications in a particular source with a Mathematics Subject Classification code (cc) in 14.
"Partial diff* eq*" ! elliptic The not-operator ! eliminates all results containing the word elliptic.
dt: b & au: Hilbert The document type is set to books; alternatively: j for journal articles, a for book articles.
py: 2000-2015 cc: (94A | 11T) Number ranges are accepted. Terms can be grouped within (parentheses).
la: chinese Find documents in a given language. ISO 639-1 language codes can also be used.

Operators
a & b logic and
a | b logic or
!ab logic not
abc* right wildcard
"ab c" phrase
(ab c) parentheses
Fields
any anywhere an internal document identifier
au author, editor ai internal author identifier
ti title la language
so source ab review, abstract
py publication year rv reviewer
cc MSC code ut uncontrolled term
dt document type (j: journal article; b: book; a: book article)
An “age”-structured model of hematopoietic stem cell organization with application to chronic myeloid leukemia. (English) Zbl 1182.92043

Summary: Previously, we have modeled hematopoietic stem cell organization by a stochastic, single cell-based approach [M. Loeffler and I. Roeder, Cells, Tissues, Organs 171, No. 1, 8–26 (2002); I. Glauche et al., Stem Cells 25, No. 7, 1791–1799 (2007)]. Applications to different experimental systems demonstrated that this model consistently explains a broad variety of in vivo and in vitro data. A major advantage of the agent-based model (ABM) is the representation of heterogeneity within the hematopoietic stem cell population. However, this advantage comes at the price of time-consuming simulations if the systems become large.

One example in this respect is the modeling of disease and treatment dynamics in patients with chronic myeloid leukemia (CML), where the realistic number of individual cells to be considered exceeds 10 6 . To overcome this deficiency, without losing the representation of the inherent heterogeneity of the stem cell population, we propose to approximate the ABM by a system of partial differential equations (PDEs). The major benefit of such an approach is its independence from the size of the system. Although this mean field approach includes a number of simplifying assumptions compared to the ABM, it retains the key structure of the model including the “age”-structure of stem cells. We show that the PDE model qualitatively and quantitatively reproduces the results of the agent-based approach.

MSC:
92C50Medical applications of mathematical biology
92C37Cell biology
35Q92PDEs in connection with biology and other natural sciences
65C20Models (numerical methods)
References:
[1]Atkinson, K.A., 1989. An Introduction to Numerical Analysis, 2nd edn. Wiley, New York.
[2]Branford, S., Hughes, T.P., Rudzki, Z., 1999. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br. J. Haematol. 107(3), 587–99. · doi:10.1046/j.1365-2141.1999.01749.x
[3]Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Müller, M., Druker, B.J., Lydon, N.B., 1996. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56(1), 100–04.
[4]Colijn, C., Mackey, M.C., 2005. A mathematical model of hematopoiesis: I. Periodic chronic myelogenous leukemia. J. Theor. Biol. 237(2), 117–32. · doi:10.1016/j.jtbi.2005.03.033
[5]Dingli, D., Michor, F., 2006. Successful therapy must eradicate cancer stem cells. Stem Cells 24(12), 2603–610. · doi:10.1634/stemcells.2006-0136
[6]d’Inverno, M., Luck, M., 2004. Understanding Agent Systems, 2nd edn. Springer, Berlin.
[7]Druker, B.J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G.M., Fanning, S., Zimmermann, J., Lydon, N.B., 1996. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2(5), 561–66. · doi:10.1038/nm0596-561
[8]Glauche, I., Cross, M., Loeffler, M., Roeder, I., 2007. Lineage specification of hematopoietic stem cells: mathematical modeling and biological implications. Stem Cells 25(7), 1791–799. · doi:10.1634/stemcells.2007-0025
[9]Hochhaus, A., Weisser, A., La Rosée, P., Emig, M., Müller, M.C., Saussele, S., Reiter, A., Kuhn, C., Berger, U., Hehlmann, R., Cross, N.C., 2000. Detection and quantification of residual disease in chronic myelogenous leukemia. Leukemia 14(6), 998–005. · doi:10.1038/sj.leu.2401811
[10]Holtz, M., Forman, S.J., Bhatia, R., 2007. Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment. Cancer Res. 67(3), 1113–120. · doi:10.1158/0008-5472.CAN-06-2014
[11]Horn, M., Loeffler, M., Roeder, I., 2008. Mathematical modeling of genesis and treatment of chronic myeloid leukemia. Cells Tissues Organs 188(1–2), 236–47. · doi:10.1159/000118786
[12]Jørgensen, H.G., Copland, M., Allan, E.K., Jiang, X., Eaves, A., Eaves, C., Holyoake, T., 2006. Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate. Clin. Cancer Res. 12(2), 626–33. · doi:10.1158/1078-0432.CCR-05-0429
[13]Kim, P.S., Lee, P.P., Levy, D., 2008a. Modeling imatinib-treated chronic myelogenous leukemia: reducing the complexity of agent-based models. Bull. Math. Biol. 70(3), 728–44. · Zbl 1142.92017 · doi:10.1007/s11538-007-9276-z
[14]Kim, P.S., Lee, P.P., Levy, D., 2008b. A PDE model for imatinib-treated chronic myelogenous leukemia. Bull. Math. Biol. doi: 10.1007/s11538-008-9336-z .
[15]LeVeque, R.J., 1990. Numerical Methods for Conservation Laws. Birkhäuser, Basel.
[16]Loeffler, M., Roeder, I., 2002. Tissue stem cells: definition, plasticity, heterogeneity, self-organization and models–a conceptual approach. Cells Tissues Organs 171(1), 8–6. · doi:10.1159/000057688
[17]Mauro, M.J., Druker, B.J., 2001. Chronic myelogenous leukemia. Curr. Opin. Oncol. 13(1), 3–. · doi:10.1097/00001622-200101000-00002
[18]Metz, J.A.J., Diekmann, O., 1986. The Dynamics of Physiologically Structured Populations. Springer, Berlin.
[19]Michor, F., 2007. Reply: the long-term response to imatinib treatment of CML. Br. J. Cancer 96(4), 679–80. · doi:10.1038/sj.bjc.6603604
[20]Michor, F., Hughes, T.P., Iwasa, Y., Branford, S., Shah, N.P., Sawyers, C.L., Nowak, M.A., 2005. Dynamics of chronic myeloid leukaemia. Nature 435(7046), 1267–270. · doi:10.1038/nature03669
[21]Roeder, I., 2003. Dynamic Modeling of Hematopoietic Stem Cell Organization–Design and Validation of the New Concept of Within-Tissue Plasticity. Dissertation, University of Leipzig, ISSN: 1610-7233.
[22]Roeder, I., Glauche, I., 2007. Pathogenesis, treatment effects, and resistance dynamics in chronic myeloid leukemia–insights from mathematical model analyses. J. Mol. Med. 86(1), 17–7. · doi:10.1007/s00109-007-0241-y
[23]Roeder, I., Loeffler, M., 2002. A novel dynamic model of hematopoietic stem cell organization based on the concept of within-tissue plasticity. Exp. Hematol. 30(8), 853–61. · doi:10.1016/S0301-472X(02)00832-9
[24]Roeder, I., Lorenz, R., 2006. Asymmetry of stem cell fate and the potential impact of the niche: observations, simulations, and interpretations. Stem Cell Rev. 2(3), 171–80. · doi:10.1007/s12015-006-0045-4
[25]Roeder, I., Kamminga, L.M., Braesel, K., Dontje, B., de Haan, G., Loeffler, M., 2005. Competitive clonal hematopoiesis in mouse chimeras explained by a stochastic model of stem cell organization. Blood 105(2), 609–16. · doi:10.1182/blood-2004-01-0282
[26]Roeder, I., Horn, M., Glauche, I., Hochhaus, A., Mueller, M.C., Loeffler, M., 2006. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat. Med. 12(10), 1181–184. · doi:10.1038/nm1487
[27]Roeder, I., Braesel, K., Lorenz, R., Loeffler, M., 2007. Stem cell fate analysis revisited: interpretation of individual clone dynamics in the light of a new paradigm of stem cell organization. J. Biomed. Biotechnol. 2007(3), 84656. · doi:10.1155/2007/84656
[28]Savage, D.G., Antman, K.H., 2002. Imatinib mesylate–a new oral targeted therapy. N. Engl. J. Med. 346(9), 683–93. · doi:10.1056/NEJMra013339
[29]Spanier, J., Oldham, K.B., 1987. The Dirac delta function δ(x). In: An Atlas of Functions, pp. 79–2. Hemisphere, Washington. Chap. 10.
[30]Vigneri, P., Wang, J.Y., 2001. Induction of apoptosis in chronic myelogenous leukaemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat. Med. 7(2), 228–34. · doi:10.1038/84683